1. Home
  2. QTTB vs GNS Comparison

QTTB vs GNS Comparison

Compare QTTB & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • GNS
  • Stock Information
  • Founded
  • QTTB 2015
  • GNS 2002
  • Country
  • QTTB United States
  • GNS Singapore
  • Employees
  • QTTB N/A
  • GNS N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • GNS Other Consumer Services
  • Sector
  • QTTB Health Care
  • GNS Real Estate
  • Exchange
  • QTTB Nasdaq
  • GNS Nasdaq
  • Market Cap
  • QTTB 18.9M
  • GNS 17.8M
  • IPO Year
  • QTTB N/A
  • GNS 2022
  • Fundamental
  • Price
  • QTTB $1.44
  • GNS $1.44
  • Analyst Decision
  • QTTB Hold
  • GNS
  • Analyst Count
  • QTTB 8
  • GNS 0
  • Target Price
  • QTTB $24.00
  • GNS N/A
  • AVG Volume (30 Days)
  • QTTB 123.8K
  • GNS 14.4M
  • Earning Date
  • QTTB 08-07-2025
  • GNS 04-30-2025
  • Dividend Yield
  • QTTB N/A
  • GNS N/A
  • EPS Growth
  • QTTB N/A
  • GNS N/A
  • EPS
  • QTTB N/A
  • GNS N/A
  • Revenue
  • QTTB N/A
  • GNS $7,912,718.00
  • Revenue This Year
  • QTTB N/A
  • GNS $233.65
  • Revenue Next Year
  • QTTB N/A
  • GNS $570.20
  • P/E Ratio
  • QTTB N/A
  • GNS N/A
  • Revenue Growth
  • QTTB N/A
  • GNS N/A
  • 52 Week Low
  • QTTB $1.38
  • GNS $0.21
  • 52 Week High
  • QTTB $53.79
  • GNS $3.20
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 36.08
  • GNS 79.64
  • Support Level
  • QTTB $1.41
  • GNS $1.27
  • Resistance Level
  • QTTB $1.63
  • GNS $1.54
  • Average True Range (ATR)
  • QTTB 0.11
  • GNS 0.22
  • MACD
  • QTTB -0.02
  • GNS 0.10
  • Stochastic Oscillator
  • QTTB 8.89
  • GNS 91.67

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.

Share on Social Networks: